POUT: Adjuvant Chemotherapy After Nephroureterectomy for Patients With UTUC

Alison Jane Birtle, MD, MBBS, MRCP, FRCR, of the Lancashire Teaching Hospitals NHS Foundation Trust, provides a final analysis of the POUT trial, which investigated the potential of adjuvant chemotherapy in improving overall survival, quality of life, and disease-specific survival in patients with upper tract urothelial carcinoma.

Dr. Birtle explains why disease-free survival was chosen as the primary end point over overall survival as well as the role of carboplatin versus cisplatin.

Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Jérémie Calais, MD, PhDProstate Cancer Diagnostics | March 7, 2024
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
View More
Saby George, MD, FACPAdvanced Renal Cell Carcinoma | March 7, 2024
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Saby George, MD, FACPAdvanced Renal Cell Carcinoma | March 7, 2024
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Thomas Powles, MBBS, MRCP, MDAdvanced Urothelial Carcinoma | March 7, 2024
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.

Video Insights

Clinical discussions with experts in the field

Network Websites